DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

B. Riley FBR Maintains Buy on Akari Therapeutics, Lowers Price Target to $5

B. Riley FBR maintains Akari Therapeutics (NASDAQ:AKTX) with a Buy and lowers the price target from $7 to $5.

Benzinga · 03/13/2020 11:29

B. Riley FBR maintains Akari Therapeutics (NASDAQ:AKTX) with a Buy and lowers the price target from $7 to $5.